S-23 is an investigational selective androgen receptor modulator (SARM) that has been studied for its potential effects on muscle and bone tissue. SARMs are a class of therapeutic compounds that aim to have similar effects to androgenic drugs like anabolic steroids but with reduced androgenic side effects. S-23 is not approved for human use and remains a research chemical. Its primary mechanism involves binding to androgen receptors in a tissue-selective manner, potentially promoting anabolic activity in muscle and bone while minimizing effects on other tissues like the prostate or sebaceous glands. Early research on S-23 has been conducted primarily in animal models.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubChem","Examine.com"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.